Bioptamers
Private Company
Funding information not available
Overview
Founded in 2016, Bioptamers is a private, pre-revenue biotech focused on revolutionizing cancer treatment through personalized, aptamer-based drug delivery. The company's core technology is a microfluidic platform for selecting synthetic molecules (aptamers) that can precisely deliver chemical, radiation, or immunological therapies directly to tumors. While still in the pre-clinical development stage, Bioptamers aims to address the significant global oncology market by improving therapeutic outcomes and reducing off-target effects. Its strategy involves academic and industry collaborations to translate its platform into clinical candidates.
Technology Platform
Proprietary microfluidic platform for the selection and development of synthetic aptamers (DNA/RNA molecules) for targeted delivery of chemical, radiation, and immunological cancer therapies. Also develops MatriXpec™ tissue-specific hydrogels and coatings for 3D/2D cell culture research.
Opportunities
Risk Factors
Competitive Landscape
Bioptamers competes in the targeted cancer therapy space with large pharmaceutical companies and biotechs developing antibody-drug conjugates (ADCs), radiopharmaceuticals, and other ligand-directed therapies. Its key differentiator is the use of aptamers instead of antibodies, which it claims offers advantages in cost, scalability, and size. It also faces competition from other aptamer-focused biotech companies.